

INDEVUS PHARMACEUTICALS INC

Form 8-K

May 19, 2003

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported):

May 13, 2003

Indevus Pharmaceuticals, Inc.

(Exact name of registrant as specified in its charter)

Delaware
(State or other
jurisdiction of
incorporation)

000-18728
(Commission
File Number)

04-3047911
(IRS Employer
Identification
Number)

One Ledgemont Center

99 Hayden Avenue

Lexington, Ma 02421-7966

(Address of principal executive offices)

(781-861-8444)

Registrant's telephone number, including area code

Item 7. Exhibits

99.1 Press Release of the Registrant dated May 13, 2003.

Item 9. Regulation FD Disclosure

The information contained in this report on Form 8-K is being furnished by Indevus Pharmaceuticals, Inc. under Item 9 of Form 8-K pursuant to Item 12 of Form 8-K as directed by the Securities and Exchange Commission in Release No. 33-8216. This information shall not be deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the Exchange Act), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

On May 13, 2003, the Company issued a press release announcing its second quarter fiscal 2003 results. A copy of the press release is attached as Exhibit 99.1 to this report.

The exhibit hereto contains forward-looking statements that involve risks and uncertainties that could cause the Company's actual results and financial condition to differ materially from those anticipated by the forward-looking statements. These risks and uncertainties are set forth in the Company's filings under the Securities Act of 1933 and the Securities Exchange Act of 1934 under Risk Factors and elsewhere, and include, but are not limited to: dependence on the success of trospium; uncertainties relating to clinical trials, regulatory approval and commercialization of our products, particularly trospium; the early stage of products under development; need for additional funds and corporate partners, including for the commercialization of trospium and the development of pagoclone; failure to acquire and develop additional product candidates; history of operating losses and expectation of future losses; product liability and insurance uncertainties; risks relating to the Redux-related litigation; dependence on third parties for manufacturing and marketing; competition; risks associated with contractual arrangements; limited patent and proprietary rights; dependence on market exclusivity; valuation of our common stock; and other risks.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: May 19, 2003

INDEVUS PHARMACEUTICALS, INC.

By: /s/ GLENN L. COOPER

Glenn L. Cooper, M.D.

President, Chief Executive

Officer and Chairman